SANTA CLARA, Calif., April 19, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has launched an e-commerce platform to support the commercialization of its Life Science products.
The launch follows the recent expansion of CrownBio’s Life Science division and answers the need to accommodate an increasing demand for the Company’s products.
CrownBio’s clients will now be able to purchase hundreds of products online across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immune checkpoint antibodies, and tumor tissue microarrays.
This digital tool facilitates and accelerates clients’ ordering, enabling them to create online accounts to track the history of their previous orders, save and share quotations for pending approval, and conveniently process transactions.
“We have created a digital user-friendly experience. Our platform has been updated to meet client expectations and provide an improved opportunity to purchase and deliver products online at CrownBio,” commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
“We remain impressed by the incredible growth and development of every division at CrownBio,” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. “In the Life Science sector, I am pleased we could successfully pivot CrownBio digital engagement efforts with the development of the e-commerce platform, which will ensure a client friendly, efficient experience to purchasing our products.”
CrownBio’s online shop can be accessed from the company website at this link https://www.crownbio.com/shop.
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Instagram Outage Disrupts Thousands of U.S. Users
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



